Although evaluating the tumor membrane expression of programmed death-ligand 1 (PD-L1) has become mandatory for newly diagnosed advanced NSCLC [2], the ICI as single-agent can achieve satisfying responses regardless of the PD-L1 status in the pretreated population [1]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.